MedPath

Two US-guided Techniques for Greater Occipital Nerve Blocks

Not Applicable
Completed
Conditions
Primary Headache
Registration Number
NCT02031822
Lead Sponsor
University Health Network, Toronto
Brief Summary

Headache is one of the most common reasons for patients to access healthcare. Greater occipital nerve (GON) block with local anesthetic and steroid has been described for the management of primary headache refractory to conventional treatment. Two ultrasound (US)-guided techniques for greater occipital nerve (GON) block have been described for the management of refractory headache syndromes: a proximal technique performed at the level of the second cervical vertebra and a distal technique performed at the level of the superior nuchal line. Our airm is to compare the accuracy, efficacy and safety of these two techniques in patients with refractory headaches.

Detailed Description

We conducted a double-blinded, randomized control trial to compare accuracy, efficacy and safety of these two techniques in patients with refractory headache syndromes. Following REB approval, 40 patients with moderate or severe refractory headaches (intensity score\>4/10) will be randomized to the "proximal" or "distal" groups with a 1:1 allocation. Each patient receives an injection of 2ml of 0.5% bupivacaine with 40mg of methylprednisolone. The null hypothesis is that there is no difference in intensity scores for headache at one month after the interventions. Outcomes related to efficacy (numbness immediately after the injection, reduction in episodes of severe headache, sleep quality), performance (time taken for and discomfort during procedure), and safety (incidence of hematoma, intravascular injection) are measured after one month.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
40
Inclusion Criteria
  1. Features suggestive of occipital neuralgia: pain that begins in the upper neck and back of the head with radiation forward toward the eye and has an aching or burning character.
  2. Diagnosis of refractory primary headache, any type
  3. Baseline NRS headache score of > 4 refractory to conventional oral analgesic therapy (anti-inflammatory drugs, migraine prophylaxis and treatment drugs, opioids).
Exclusion Criteria
  1. Ongoing litigation issues related to the patient's pain
  2. Pregnancy
  3. Allergy to steroids or local anesthetics
  4. Multiple serious comorbidities
  5. Age < 18 or age ≥ 80 years
  6. GON injection within last 3 months at time of entry into the trial

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Numerical rating score (NRS) for headachesOne month
Secondary Outcome Measures
NameTimeMethod
Safety-Related OutcomesImmediate post-procedure and at 1 month

Any immediate post intervention complications will be recorded (e.g. hematoma, vascular puncture, dizziness). Occurrence of any long-term adverse effects (e.g. infection, numbness, alopecia) will be recorded at 1 month following the intervention.

Efficacy-Related Outcomes24 hours and 3 months

This would include NRS for headache at 24 hrs and 3 months after the intervention, patient satisfaction with the block, Hospital Anxiety and Depression Scale at 1 month compared to baseline, SF-36 Short Form Health Survey to measure improvement in functional status compared to baseline, quality of sleep and average hours of restful sleep at night.

Performance-Related OutcomesDuring procedure

We will measure performance time from contact of US probe with skin to the end of the procedure, procedural discomfort as rated by NRS, number of needle re-adjustments and evidence of sensory block as confirmed by the loss of pin-prick sensation in the dermatomal distribution of GON, and visualization of GON.

Trial Locations

Locations (2)

Mount Sinai Hospital

🇨🇦

Toronto, Ontario, Canada

Toronto Western Hospital, University Health Network

🇨🇦

Toronto, Ontario, Canada

Mount Sinai Hospital
🇨🇦Toronto, Ontario, Canada

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.